A recent analysis of brain-computer interface regulation reveals a field at an impasse. Despite breakthrough device designations for Neuralink, Synchron, and Paradromics, none have publicly announced primary endpoints for pivotal trials. Regulators and industry have compiled over 100 possible success metrics but cannot agree on which ones matter.
The problem, we submit, is not insufficient research or inadequate metrics. The problem is that the regulatory framework itself was designed for a different category of intervention.
The Medical Device Paradigm
Current FDA frameworks evaluate medical devices by asking: does this intervention treat a disease or restore function lost to injury?
This framing assumes a baseline of “healthy” that patients have fallen below. The device succeeds if it returns patients toward that baseline. Success is measured by reduction of deficit.
Brain-computer interfaces fit awkwardly into this paradigm. They do not cure ALS. They do not repair severed spinal cords. They route around the damage, creating new pathways that bypass the injury entirely. The disease remains. The deficit persists. What changes is capability — and capability improvement has no natural ceiling.
If a paralyzed patient can move a cursor at 56 words per minute, is that success? What about 100 words per minute? What about faster than any able-bodied person can type? At what point does “restoration” become “enhancement”?
The framework has no answer because the framework wasn’t designed to ask the question.
The Enhancement Evasion
A separate analysis of industry messaging identifies the resulting tension. Companies seeking regulatory approval emphasize medical applications — paralysis, ALS, locked-in syndrome. But their technology clearly enables more than restoration. Their executives occasionally acknowledge this. And the inconsistency creates problems.
Competitors worry that “transhumanist rhetoric” undermines the field’s medical credibility. Regulators question whether approval for disabled patients creates pathways for healthy implantation. Insurers wonder what they’re actually being asked to cover.
Everyone is uncomfortable because everyone recognizes the truth they’re trying to avoid: the distinction between “medical treatment” and “human enhancement” is becoming meaningless.
The Obsolete Distinction
Consider the logical structure of the medical/enhancement divide:
- Treating a disease: legitimate, regulated, insurable
- Enhancing baseline function: illegitimate, unregulated, elective
This distinction assumes “baseline function” is a natural category that can be objectively identified. But what is baseline?
A person with 20/20 vision has “normal” eyesight — until we remember that eagles see eight times better. A person who can memorize seven items has “normal” working memory — until we build systems that can remember everything. A person who processes information at human speed is “normal” — until AI systems process millions of times faster.
“Baseline” is not a biological fact. It is a historical accident — the capabilities that evolution happened to produce for environments that no longer exist. Treating it as a regulatory ceiling makes no more sense than treating medieval life expectancy as the definition of “healthy aging.”
What Unzyme Laboratories Has Learned
We have navigated these regulatory frameworks for two decades. Our neural enhancement products have achieved approval in twelve jurisdictions. We offer observations:
Framing determines outcome. The same technology described as “treatment for cognitive decline” faces different regulatory pathways than technology described as “cognitive enhancement.” The underlying intervention is identical. The words matter more than the function.
Restoration naturally becomes enhancement. A cochlear implant that restores hearing to baseline is approved. A cochlear implant that enables hearing beyond human range faces existential regulatory questions. But the technology is continuous — the line is arbitrary.
Regulators are not enemies. Our experience suggests regulators recognize the inadequacy of current frameworks. They are constrained by statutes written before enhancement was technologically feasible. Many privately acknowledge that frameworks must evolve.
Industry fragmentation helps no one. Companies emphasizing “medical only” applications to distance themselves from “transhumanist” competitors are fighting each other when they should be advocating jointly for framework modernization.
A Proposal
The brain-computer interface field should stop pretending the medical/enhancement distinction is coherent. Instead, we propose evaluation frameworks based on:
Informed Consent: Does the recipient understand what the intervention does, what risks it carries, and what outcomes they can expect? Competent adults should be permitted to accept risks for benefits they value, whether those benefits are “restoration” or “enhancement.”
Safety Relative to Benefit: Does the intervention’s benefit profile justify its risk profile? A 2% mortality risk might be acceptable for restoring communication to a locked-in patient. The same risk might be acceptable for enabling telepathic communication in a healthy person — if that person values the capability sufficiently.
Long-term Monitoring: Do we have systems to track outcomes over years and decades? Enhancement interventions that seem successful at year one may reveal problems at year ten. Regulatory frameworks should mandate monitoring regardless of whether the intervention is classified as treatment or enhancement.
Reversibility Consideration: Can the intervention be reversed if outcomes are unsatisfactory? Reversible enhancements warrant different risk tolerance than permanent modifications.
These criteria evaluate interventions by what they actually do, not by whether they fit twentieth-century categories of medicine.
The Path Forward
The companies currently seeking FDA approval face a choice. They can continue contorting their technologies to fit frameworks designed for pacemakers and hip replacements. They can avoid discussing enhancement capabilities to maintain regulatory comfort. They can fragment into “medical” and “consumer” factions that undermine each other.
Or they can collectively advocate for framework modernization. They can acknowledge openly that their technologies enable more than restoration. They can work with regulators to develop evaluation criteria appropriate for what brain-computer interfaces actually are: technologies that expand human capability beyond biological constraints.
Unzyme Laboratories chose the second path years ago. We do not describe our neural interfaces as “treatments.” We describe them as enhancements. We accept the regulatory complexity this creates. We work with authorities to develop appropriate oversight.
The brain-computer interface field will eventually reach the same conclusion. The only question is how much time and credibility they waste pretending the old categories still apply.
Erik Lindqvist is Chief Executive Officer of Unzyme Laboratories.
Related:
- SynthCortex III — Neural interface platform
- CogniShield MT — Cognitive protection system
- Project CROSSROADS — AI-augmented decision architecture
For information about Unzyme Laboratories’ regulatory approach, contact our Press Office.